Literature DB >> 19368957

Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.

Jonathan Strosberg1, Aejaz Nasir, Domenico Coppola, Mark Wick, Larry Kvols.   

Abstract

Three-tiered grading systems (low, intermediate, and high grade) have been proposed for neuroendocrine tumors. These classifications have not been rigorously evaluated in neuroendocrine malignancies of the digestive tract. We performed a retrospective chart analysis of 83 patients with metastatic gastroenteropancreatic neuroendocrine tumors, correlating tumor grade with overall survival. We also analyzed available biopsy specimens (on 40 patients), examining hematoxylin and eosin stains for mitotic rate and immunostaining for measurement of the Ki-67 index. Tumor grades were assigned based on the mitotic rate and the Ki-67 index, and the prognostic validity of each grading method was assessed. A highly significant correlation existed between the reported tumor grade and overall survival. Five-year survival rates for patients with low-, intermediate-, and high-grade tumors were 87%, 38%, and 0%, respectively. On biopsy specimen analysis, both mitotic rates and Ki-67 indexes correlated strongly with overall survival. We conclude that a 3-tiered grading classification for gastroenteropancreatic neuroendocrine tumors correlates with survival in the metastatic setting. Both mitotic rates and Ki-67 indexes are inversely associated with survival and can be analyzed independently for assignment of grade.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368957     DOI: 10.1016/j.humpath.2009.01.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  37 in total

1.  High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma.

Authors:  T Akaike; J Qazi; A Anderson; F S Behnia; M M Shinohara; G Akaike; D S Hippe; H Thomas; S R Takagishi; K Lachance; S Y Park; E S Tarabadkar; J G Iyer; A Blom; U Parvathaneni; H Vesselle; P Nghiem; S Bhatia
Journal:  Br J Dermatol       Date:  2020-06-16       Impact factor: 9.302

2.  A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.

Authors:  James D Smith; Diane L Reidy; Karyn A Goodman; Jinru Shia; Garrett M Nash
Journal:  Ann Surg Oncol       Date:  2014-04-24       Impact factor: 5.344

3.  Breast and lung metastasis from pancreatic neuroendocrine carcinoma.

Authors:  Shevonne Satahoo-Dawes; Joshua Palmer; Eddie W Manning; Joe Levi
Journal:  World J Radiol       Date:  2011-01-28

4.  Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.

Authors:  Amir Sabet; Feras Khalaf; Torjan Haslerud; Abdullah Al-Zreiqat; Amin Sabet; Birgit Simon; Thorsten D Pöppel; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-09-19

Review 5.  Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?

Authors:  Michael S Lee; Bert H O'Neil
Journal:  J Gastrointest Oncol       Date:  2016-10

6.  Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors.

Authors:  Brian R Untch; Keisha P Bonner; Kevin K Roggin; Diane Reidy-Lagunes; David S Klimstra; Mark A Schattner; Yuman Fong; Peter J Allen; Michael I D'Angelica; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham; Laura H Tang
Journal:  J Gastrointest Surg       Date:  2014-01-22       Impact factor: 3.452

Review 7.  Management of pulmonary neuroendocrine tumors.

Authors:  Robert A Ramirez; Aman Chauhan; Juan Gimenez; Katharine E H Thomas; Ioni Kokodis; Brianne A Voros
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

8.  Secondary malignancy in patients with sporadic neuroendocrine neoplasia.

Authors:  M Krausch; A Raffel; M Anlauf; M Schott; N Lehwald; A Krieg; F Kröpil; K Cupisti; W T Knoefel
Journal:  Endocrine       Date:  2013-03-14       Impact factor: 3.633

9.  Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome.

Authors:  Buddha Gurung; Zijie Feng; Daniel V Iwamoto; Austin Thiel; Guanghui Jin; Chen-Min Fan; Jessica M Y Ng; Tom Curran; Xianxin Hua
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

10.  Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.

Authors:  Gabriele Carlinfante; Paola Baccarini; Debora Berretti; Tiziana Cassetti; Maurizio Cavina; Rita Conigliaro; Alessandro De Pellegrin; Luca Di Tommaso; Carlo Fabbri; Adele Fornelli; Andrea Frasoldati; Giorgio Gardini; Luisa Losi; Livia Maccio; Raffaele Manta; Nico Pagano; Romano Sassatelli; Silvia Serra; Lorenzo Camellini
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.